Cardiovascular disease (CVD) is associated with more deaths than all cancers—and more deaths in women than breast cancer. This Cardiovascular Risk Profile evaluates a thorough battery of traditional and advanced biomarkers to aid in early detection and modification of risk factors. Doctor's Data measures the activity of lipoprotein-associated phospholipase-A2 (PLAC), as well as the true LDL culprits; oxidized LDL, small dense LDL and Lp(a), which are higher in CVD patients and correlated with the severity of CVD. A total of thirteen primary and secondary risk factors are evaluated to provide actionable information at a tremendous value.
Learn more »
5 to 7 days
Click any analyte name for additional clinical information, including reference ranges, specimen collection, stability and rejection criteria.
|Apolipoprotein, A1; serum||82172||Yes|
|Apolipoprotein, B, serum||82172||Yes|
|C-Reactive Protein; serum||86141||No|
|Lipoprotein (a), serum||83695||No|
|Non-HDL Cholesterol; serum||*||Yes|
|Oxidized LDL; serum||83520||No|
|PLAC (LP-PLA2 Activity); serum||83698||Yes|
|small dense LDL; serum||84999||Yes|
List price applies when filing with insurance or Medicare, or when billing a patient directly.
Prompt payment pricing applies when billing to a physician account or prepayment is received with the test.
Doctor's Data offers profiles containing multiple analytes. *Multiple analytes may be billed under a single CPT code. Many analytes can be ordered individually. Pricing may vary. Click on a specific analyte for more information or read our detailed billing and payment policies.
The CPT codes listed on our website are for informational purposes only. This information is our interpretation of CPT coding requirements and may not necessarily be correct. You are advised to consult the CPT Coding Manual published by the American Medical Association. Doctor's Data, Inc. takes no responsibility for billing errors due to your use of any CPT information from our website.
Cardiovascular disease (CVD) is associated with more deaths than all cancers—and more deaths in women than breast cancer. The Cardiovascular Risk Profile from Doctor's Data reviews a thorough battery of biomarkers to aid in early detection and reduction of risk factors before the disease progresses. The enzymatic activity of lipoprotein-associated phospholipase-A2 (PLAC) provides an indication of very significant atherogenic disease activity, inflammation and increased risk for rupture of advanced plaque. Elevated PLAC activity is a very strong predictor of coronary events and CD-related mortality regardless of cholesterol levels.